CARMA Therapeutics is being built upon innovative technology from the Center for Cellular Immunotherapies at the University of Pennsylvania, and was spun out from the laboratory of Saar Gill, MD, PhD, assistant professor of Hematology Oncology in the Perelman School of Medicine at the University of Pennsylvania. 'We hypothesized early on that focusing on different effector cells, other than T cells, might be more effective in trying to tackle solid tumors, which has been a challenge for T cell therapies. The innate biology drove us to try macrophages,' says Dr. Gill, co-founder of CARMA Therapeutics, who conducts bench and clinical research on chimeric antigen receptor (CAR) T cells, and now on CAR macrophages.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
06/12/17	undisclosed	First Round	AbbVie Biotech Ventures Grazia Equity HealthCap IP Group	undisclosed